Pfizer has announced it will make a EUR 300-million ($351-million) capital investment in its Irish operations to support the further development of its existing manufacturing sites in Grange Castle, Newbridge, and Ringaskiddy.

The investment will provide additional manufacturing and laboratory capacity and create approximately 300 positions. The investment and roles being created will upgrade and enhance existing facilities, expand manufacturing and laboratory capacity, and add new technologies. The investment and additional roles will be completed over the next two to three years (as reported on November 2, 2020).

Part of the investment includes a project to construct a development facility on the existing Ringaskiddy site to manufacture pharmaceutical compounds for Pfizer’s clinical trials globally.

Source: IDA Ireland